Bypassing Patent Trolls in Pharma using Blockchain Tokenization

The pharmaceutical and biotech industries suffer heavily from patent trolls—entities that hoard intellectual property purely for litigation. Digital rights tokenization offers a structural solution that protects true innovators and accelerates global R&D.

Democratizing Pharma IP

By utilizing our platform, pharmaceutical researchers can list their patents as digital assets. Our system operates on a dual-token model: mass Non-Exclusive Tokens and a single Exclusive Token. Instead of waiting for a massive corporate buyout (or falling prey to trolls), researchers can set a fixed price and strict emission limit (up to 1 trillion units) to instantly sell non-exclusive digital rights to thousands of labs worldwide. This generates immediate R&D capital while retaining the underlying asset.

Protection Through Exclusivity

When a major pharma enterprise finally decides to acquire the technology entirely, they purchase the Exclusive Token. At this precise moment, the smart contract algorithmically blocks all future primary sales of non-exclusive tokens. The enterprise gains the strategic moat they require. Meanwhile, previous non-exclusive token holders maintain their rights and can trade them freely on a decentralized secondary market.

The Financial Edge

We empower creators without draining their resources. The platform only takes a 2.5% fee on primary transactions. There are no ongoing royalties. Transactions can occur in fiat or cryptocurrency.

Access is streamlined via our web app, Telegram, or WhatsApp interfaces (we intentionally do not use a separate mobile app). Protect your pharmaceutical innovations and fund your research efficiently today.